• In recent weeks, ImmunityBio reported new indirect comparison data suggesting ANKTIVA plus BCG may offer stronger responses and fewer side effects than other approved bladder cancer therapies, alongside FDA acceptance of a supplemental Biologics License Application and exclusive U.S. rights to develop and supply the Tokyo-172 BCG strain.
• These developments, combined with fresh U.S. patents protecting the ANKTIVA plus BCG franchise through at least 2035, deepen ImmunityBio’s integration across both the drug and BCG supply sides of non-muscle invasive bladder cancer care.
• With the FDA now reviewing ANKTIVA’s potential label expansion, we’ll examine how this could reshape ImmunityBio’s investment narrative and future optionality.

Capitalize on the AI infrastructure supercycle with our selection of the 44 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

ImmunityBio Investment Narrative Recap

To own ImmunityBio, you have to believe ANKTIVA can anchor a durable bladder cancer franchise while the broader pipeline slowly catches up. In the near term, the key catalyst is the FDA’s review of ANKTIVA’s label expansion in BCG unresponsive NMIBC, while the biggest risk is the company’s heavy dependence on this single asset amid large ongoing losses. The latest comparison data and BCG moves look supportive here, but do not remove that core concentration risk.

The most directly relevant update is the FDA’s acceptance of ImmunityBio’s supplemental BLA to include BCG unresponsive papillary disease without CIS, with a PDUFA action date of 6 January 2027. If the agency ultimately broadens ANKTIVA’s label, it could make the new ANKTIVA plus BCG patents and the Tokyo 172 BCG supply deal more meaningful by tying stronger intellectual property and additional BCG capacity to a potentially larger treated population.

Yet against this promising setup, investors should also be aware that ongoing securities class actions tied to earlier ANKTIVA promotion could still...

ImmunityBio's narrative projects $1.2 billion revenue and $435.5 million earnings by 2029. This requires 118.9% yearly revenue growth and an earnings increase of about $787 million from -$351.4 million today.

Uncover how ImmunityBio's forecasts yield a $13.50 fair value, a 68% upside to its current price.

Exploring Other Perspectives

Before this news, the most bearish analysts still penciled in about US$895,300,000 of 2029 revenue but worried that ANKTIVA centric adoption and global reimbursement might lag, so if you lean toward their more cautious view on bladder cancer and lung expansion you may see these data and regulatory steps as only the start of a debate that could shift their narrative over time.

Explore 9 other fair value estimates on ImmunityBio - why the stock might be worth over 4x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your ImmunityBio research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free ImmunityBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ImmunityBio's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Uncover the next big thing with 27 elite penny stocks that balance risk and reward.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.